High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients
Table 1
Characteristics of the patients in the study.
miR122_H groupc (n = 294)
miR122_L groupc (n = 294)
value
Baseline characteristics
Male (n, %)
254 (86.4)
245 (83.3)
0.300
Age (yrs, mean ± SD)a
54.9 ± 12.7
55.4 ± 13.8
0.646
HBeAg positive (n, %)
59 (20.1)
68 (23.1)
0.367
HBV-DNA positive (n, %)a,b
73 (24.8)
77 (26.2)
0.705
Serum ALB (g/L, mean ± SD)a
32.9 ± 2.3
33.0 ± 2.4
0.570
Serum TBIL (μmol/L, mean ± SD)a
14.2 ± 4.6
13.7 ± 5.0
0.219
Serum AFP (ng/mL, mean ± SD)a
302.2 ± 155.3
338.4 ± 152.0
0.004
ECOG score (n, %) a
0 points
119 (40.5)
135 (45.9)
0.183
1 point
175 (59.5)
159 (54.1)
Maximum diameter of tumor (n, %)
＜5 cm
136 (46.3)
115 (39.1)
0.197
5∼10 cm
146 (49.7)
154 (52.4)
0.062
＞10 cm
12 (4.1)
25 (8.5)
Number of tumors (n, %)
Single
228 (77.6)
202 (68.7)
0.016
Multiple
66 (22.4)
92 (31.3)
Extent of tumor (n, %)
Unilateral
263 (89.5)
244 (83.0)
0.023
Bilateral
31 (10.5)
50 (17.0)
Portal vein invasion (n, %)
Absent
5 (1.7)
6 (2.0)
0.666
Unilateral
191 (65.0)
176 (59.9)
0.214
Bilateral or main
98 (33.3)
112 (38.1)
Hepatic vein invasion (n, %)
Absent
273 (92.9)
266 (90.5)
0.296
Present
21 (7.1)
28 (9.5)
SOR treatment
Duration of SOR (week, mean ± SD)a
16.7 ± 4.1
16.3 ± 4.0
0.294
Overall adverse events (n, %)
273 (92.9)
281 (95.6)
0.158
Serious adverse events (n, %)
6 (2.0)
8 (2.7)
0.589
aSD: standard deviation; HBV: hepatitis B virus; ALB: albumin; TBIL: total bilirubin; AFP: α-fetoprotein; ECOG: eastern cooperative oncology group; SOR: sorafenib. bPositive HBV-DNA was defined as HBV-DNA ≥ 103 copies/ml. cThe patients were divided into the miR122_H group and the miR122_L group according to the median of serum miRNA-122 concentration.
